PharmaCyte Biotech, Inc.(PMCB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PMCB PharmaCyte Biotech, Inc.

Trading 05-19 13:32:05 EDT

0.7546

-0.0054

-0.71%

High0.7979	Low0.7300	Vol102.13K
Open0.7797	D1 Closing0.7600	Amplitude8.93%
Mkt Cap8.10M	Tradable Cap7.52M	Total Shares10.74M
T/O76.39K	T/O Rate1.03%	Tradable Shares9.96M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PMCB","market":"US","secType":"STK","nameCN":"PharmaCyte Biotech, Inc.","latestPrice":0.7546,"timestamp":1779211915307,"preClose":0.76,"halted":0,"volume":102133,"delay":0,"changeRate":-0.007105263157894685,"floatShares":9960100,"shares":10735649,"eps":-1.007956,"marketStatus":"Trading","change":-0.0054,"latestTime":"05-19 13:32:05 EDT","open":0.7797,"high":0.7979,"low":0.73,"amount":76393.95813298,"amplitude":0.089342,"askPrice":0.7566,"askSize":400,"bidPrice":0.7526,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.007956,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779220800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.76,"preHourTrading":{"tag":"盘前","latestPrice":0.78,"preClose":0.76,"latestTime":"09:19 EDT","volume":12267,"amount":9797.08665528,"timestamp":1779196763652,"change":0.02,"changeRate":0.026316,"amplitude":0.038684},"postHourTrading":{"tag":"盘后","latestPrice":0.8248,"preClose":0.76,"latestTime":"19:44 EDT","volume":2115,"amount":1690.6696,"timestamp":1779147864306,"change":0.0648,"changeRate":0.085263,"amplitude":0.065526},"volumeRatio":0.219522,"impliedVol":0.6721,"impliedVolPercentile":0.3944},"requestUrl":"/m/hq/s/PMCB","defaultTab":"news","newsList":[{"id":"2624682962","title":"PharmaCyte Biotech shareholders approved 2 million-share increase to 2022 equity plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682962","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682962?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:22","pubTimestamp":1775161341,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech held its annual shareholder meeting on March 30, 2026, for fiscal year ended April 30, 2026.Shareholders backed an amendment to 2022 Equity Incentive Plan, lifting share pool for future awards by 2,000,000 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL908DLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601828643","title":"Director Jonathan Schechter Acquires Common Shares of PharmaCyte Biotech Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828643","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601828643?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:43","pubTimestamp":1767825826,"startTime":"0","endTime":"0","summary":"Jonathan Schechter, Director, reported the acquisition of common shares of PharmaCyte Biotech Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL4lqhs4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Jonathan Schechter Acquires Common Shares of PharmaCyte Biotech Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591280621","title":"PharmaCyte Biotech Delays Quarterly Financial Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2591280621","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591280621?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:00","pubTimestamp":1765832458,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the financial period ended October 31, 2025. The company cited the need for additional time to prepare and review its financial statements, and expects to file the report within five calendar days following the original deadline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL6Sptt1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"PharmaCyte Biotech Delays Quarterly Financial Filing","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589848589","title":"PharmaCyte Biotech Inc - Receives Notice of Non-Compliance With Nasdaq Rule - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589848589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589848589?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:05","pubTimestamp":1764972347,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589848536","title":"PharmaCyte Biotech : Will Consider All Available Options to Regain Compliance, Including, IF Appropriate, Implementing Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2589848536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589848536?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:05","pubTimestamp":1764972347,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0IU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589366848","title":"PharmaCyte Biotech Faces Nasdaq Delisting Risk Over Bid Price Rule Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2589366848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589366848?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:01","pubTimestamp":1764972072,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. has received a notice from the Nasdaq Stock Market indicating non-compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550. The company now has 180 calendar days, until June 1, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not achieved within this period, PharmaCyte may be eligible for an additional 180-day extension if other initial listing requirements are met. Failure to regain compliance could result in the company's securities being delisted from the Nasdaq Capital Market. The notice does not affect the company's business operations or its SEC reporting obligations.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL70lRpF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586471515","title":"PharmaCyte sells Femasys stake, sees cash position rising to $20M","url":"https://stock-news.laohu8.com/highlight/detail?id=2586471515","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586471515?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:25","pubTimestamp":1764080720,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech (PMCB) announced the successful monetization of its stake in Femasys (FEMY). Following the monetization of the stake, PharmaCyte...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pharmacyte-sells-femasys-stake-sees-cash-position-rising-to-20m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pharmacyte-sells-femasys-stake-sees-cash-position-rising-to-20m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMCB","BK4139","BK4539","FEMY","BK4082","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586795734","title":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment","url":"https://stock-news.laohu8.com/highlight/detail?id=2586795734","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586795734?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10UM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586479578","title":"PharmaCyte Biotech Inc: Plans to Continue Pursuing Value-Accretive Investment Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2586479578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586479578?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10UM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584965182","title":"PharmaCyte Biotech Issues Correction to Financial Statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2584965182","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584965182?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:07","pubTimestamp":1763500045,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. has issued an amendment to its current report, updating financial statements for the years ended December 31, 2024 and 2023. The amendment includes details on the issuance of Series G Preferred Stock and related warrants, as well as information about employee benefit plan contributions and changes to the Series G Certificate of Designations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL2pPXHf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2580497415","title":"PharmaCyte Biotech Inc. held a special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580497415","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580497415?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:06","pubTimestamp":1761941166,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech Inc. held a special meeting of stockholders on October 30, 2025. Stockholders approved the issuance of shares of common stock underlying convertible preferred stock and warrants. An amendment to the 2022 Equity Incentive Plan to increase the number of shares available for grant by 2,250,000 shares was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL1fYCly:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMCB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharmacyte.com","stockEarnings":[{"period":"1week","weight":0.0937},{"period":"1month","weight":0.0431},{"period":"3month","weight":0.1665},{"period":"6month","weight":0.0644},{"period":"1year","weight":-0.283},{"period":"ytd","weight":0.0497}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.275918},{"month":2,"riseRate":0.5,"avgChangeRate":0.084919},{"month":3,"riseRate":0.25,"avgChangeRate":-0.129966},{"month":4,"riseRate":0.5,"avgChangeRate":-0.039461},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.081664},{"month":6,"riseRate":0.5,"avgChangeRate":0.058308},{"month":7,"riseRate":0.25,"avgChangeRate":-0.101838},{"month":8,"riseRate":0.125,"avgChangeRate":-0.172017},{"month":9,"riseRate":0.625,"avgChangeRate":0.071622},{"month":10,"riseRate":0.25,"avgChangeRate":-0.073172},{"month":11,"riseRate":0.25,"avgChangeRate":-0.078728},{"month":12,"riseRate":0.25,"avgChangeRate":-0.023475}],"exchange":"NASDAQ","name":"PharmaCyte Biotech, Inc.","nameEN":"PharmaCyte Biotech, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PharmaCyte Biotech, Inc.(PMCB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PharmaCyte Biotech, Inc.(PMCB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PharmaCyte Biotech, Inc.,PMCB,PharmaCyte Biotech, Inc.股票,PharmaCyte Biotech, Inc.股票老虎,PharmaCyte Biotech, Inc.股票老虎国际,PharmaCyte Biotech, Inc.行情,PharmaCyte Biotech, Inc.股票行情,PharmaCyte Biotech, Inc.股价,PharmaCyte Biotech, Inc.股市,PharmaCyte Biotech, Inc.股票价格,PharmaCyte Biotech, Inc.股票交易,PharmaCyte Biotech, Inc.股票购买,PharmaCyte Biotech, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PharmaCyte Biotech, Inc.(PMCB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PharmaCyte Biotech, Inc.(PMCB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction